Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Coherus BioSciences Q2 Adj. EPS $(0.34) Misses $(0.28) Estimate, Sales $10.254M Miss $10.946M Estimate

Author: Benzinga Newsdesk | August 07, 2025 04:16pm
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 22.74 percent. This is a 142.86 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $10.254 million which missed the analyst consensus estimate of $10.946 million by 6.32 percent. This is a 0.41 percent decrease over sales of $10.296 million the same period last year.

Posted In: CHRS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist